QX ONE™ Droplet Digital™ PCR System
The QX ONE Droplet Digital PCR System integrates droplet generation, thermal cycling, droplet reading, and analysis into a single automated precision platform that delivers superior precision and accuracy and absolute quantification.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The QX ONE Droplet Digital PCR System integrates droplet generation, thermal cycling, droplet reading, and analysis into a single automated precision platform that delivers superior precision and accuracy and absolute quantification.
WALK-AWAY OPERATION
- Four color channels combined with amplitude multiplexing and/or radial multiplexing allow for multiple unique targets to be detected in a single reaction
- Specially formulated ddPCR Multiplex Supermix is optimized to empower advanced multiplexing in probe-based assays
ADVANCED MULTIPLEXING
- Simple, intuitive run setup using a large onboard touch screen
- Optimized plate setup means fewer handling steps, fewer operator errors, and faster onboarding
EASY TO USE
- QX ONE Software, Regulatory Edition is a robust package that enables U.S. FDA 21 CFR Part 11 compliance and offers audit trails with tracked protocol changes for regulatory requirements
- RFID barcoded consumables allow lot management and traceability
REGULATORY COMPLIANT
- QX ONE Software, Regulatory Edition is a robust package that enables U.S. FDA 21 CFR Part 11 compliance and offers audit trails with tracked protocol changes for regulatory requirements
- RFID barcoded consumables allow lot management and traceability
ctDNA analysis across the cancer research continuum
In this application note, Bio-Rad discusses the transformative impact of circulating tumor DNA (ctDNA) analysis on cancer research. Unlike invasive biopsies, ctDNA analysis offers a non-invasive, safer, and more efficient method for continuously monitoring tumor-derived genomic biomarkers, tumor evolution, treatment response, and recurrence. This approach, utilizing biofluid samples like blood, urine, plasma, and saliva, provides valuable prognostic information, enabling informed decisions about therapeutic strategies. The minimally invasive nature of ctDNA collection allows for easy repetition, facilitating longitudinal analyses. This longitudinal insight helps researchers monitor evolving tumor biology, detect emergent resistant mutations, and enhance the accuracy of predictive assays, ultimately advancing cancer research and treatment.
A peer-reviewed validation of droplet digital PCR as a powerful tool for cell therapy studies
Cell and gene therapies have gained increased attention in recent years due to their potential to treat a variety of diseases, including cancer, autoimmune diseases, and genetic disorders. In this application note from Bio-Rad, explore results from a recent study, where authors note that existing qPCR assays quantifying Arthrobacter luteus (Alu) elements (Alu-qPCR) or the retrotransposon LINE1 (LINE1-qPCR) have several drawbacks. Furthermore, discover how the use of ddPCR technology allows assays to be run with a single surrogate calibration curve and optimized for multiplexing.
Viral titer determination
Recombinant adeno-associated virus (AAV) is rapidly becoming the vector of choice for human gene therapy applications due to the ability to achieve prolonged gene expression in a variety of tissues without a significant immune response or toxicity. Bio-Rad has discovered a number of novel AAV serotypes with enhanced gene expression and alternate tissue tropisms and has pioneered the study of these vectors for gene delivery. In this application note, Bio-Rad contrasts and compares the benefits of Droplet Digital PCR (ddPCR) versus quantitative PCR (qPCR) in the determination of adeno-associated virus (AAV) vector genome titers.
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital PCR technology
Droplet Digital PCR in immuno-oncology: Advancing quality control, biomarker discovery, and liquid biopsy monitoring
Explore the versatile role of ddPCR technology in immuno-oncology for precise and sensitive nucleic acid quantification
